GSK

Business Context and Reporting Period

This Form 6-K filing by GlaxoSmithKline plc (GSK) dated March 9, 2021, announces the publication of the Annual Report for the year ended December 31, 2020. The filing serves as a notification to the US Securities and Exchange Commission regarding the availability of the Annual Report and the Notice of the Annual General Meeting 2021. The document primarily details the company's principal risks and uncertainties, governance structures, and related party transactions rather than providing a full set of audited financial statements.

Key Financial Metrics

The filing text does not provide a comprehensive set of financial metrics such as total revenue, net profit, operating cash flow, or debt levels for the 2020 period. Specific financial data is limited to related party transactions and specific liabilities disclosed in Appendix C:

• Related Party Royalties: Royalties due from GSK to Innoviva Inc. were £261 million for the year ended December 31, 2020 (compared to £215 million in 2019).
• Related Party Payables: The balance payable by GSK to Innoviva Inc. was £65 million at year-end (compared to £63 million in 2019).
• Investments and Loans: GSK held a £3.0 million loan receivable from Medicxi Ventures I LP. Additional investments were made in Kurma Biofund II (£0.8 million), Apollo Therapeutics LLP (£2.0 million), and Medicxi Ventures I LP (£1.2 million).
• Joint Venture Obligations: An outstanding liability of $17 million was due to Qura Therapeutics LLC as of December 2020.
• Cash Distributions: GSK received cash distributions of £14.5 million from Medicxi Ventures I LP and £10.6 million from Index Venture VI (Jersey) LP.

For full financial results, the filing directs investors to the Annual Report 2020 and the unaudited preliminary results announcement released on February 3, 2021.

Material Changes and Strategic Context

The filing highlights significant strategic and operational changes impacting the company's risk profile and future structure:

• Corporate Transformation: GSK is executing a "Future Ready" programme to separate into two standalone companies: New GSK (a biopharma company) and a new Consumer Healthcare company. This separation is a two-year programme aimed at improving capital allocation and operational efficiency.
• Risk Management Evolution: The company shifted from annual to quarterly reporting for most principal risks to enable more dynamic oversight. Board oversight was extended to include the Corporate Responsibility Committee and Science Committee.
• Environmental Commitments: In November 2020, GSK announced a commitment to achieve net zero climate impact and be net nature positive by 2030.
• Operational Incidents: The company reported two employee fatalities in 2020 (one at a manufacturing site in Canada and one in a road traffic accident in India) and one work-related fatality involving a construction worker in Belgium, prompting a new safety improvement plan.

Guidance, Outlook, and Risks

The filing includes a cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to various risks. Key risks and management commentary include:

• Regulatory and Compliance: GSK faces evolving regulations regarding product quality (e.g., EMA requirements on sterile medicinal products), data privacy (GDPR and Schrems II ruling), and anti-bribery/corruption (ABAC). The company is actively updating controls to address nitrosamine impurities and cyber threats.
• Commercial and Pricing: The company notes continued downward price pressure in major markets and the challenges of the global COVID-19 pandemic. GSK is adapting to digital landscapes and enhancing oversight of digital marketing and commercial practices.
• Supply Chain: Supply continuity remains a critical risk due to reliance on third-party suppliers and potential disruptions from natural events, geopolitical issues, or pandemics. GSK has prioritized the supply of pandemic medicines and vaccines.
• Research and Development: Risks include the failure to obtain regulatory approvals, patent expirations leading to generic competition, and data integrity issues. The company is investing in modernizing regulatory information management systems.
• Information Security: The company faces sophisticated cyber threats, including ransomware attacks targeting the healthcare sector. GSK is investing in modernizing cyber operations and operational technology (OT) security.

Important Facts for Investor Verification

• Verify the full financial performance (revenue, profit, cash flow) in the Annual Report 2020 or the preliminary results announcement dated February 3, 2021, as this Form 6-K does not contain these figures.
• Review the status and progress of the "Future Ready" separation programme, including the timeline and potential impact on capital allocation and operational costs.
• Assess the impact of the two employee fatalities and the subsequent safety improvement plan on operational continuity and reputation.
• Monitor the company's progress toward its 2030 net zero climate impact and net nature positive commitments, including potential costs associated with these initiatives.
• Examine the details of unresolved legal proceedings and litigation risks, particularly those related to product liability, patent disputes, and commercial practices, as referenced in Note 46 of the Annual Report.
• Confirm the effectiveness of GSK's cybersecurity measures and third-party risk management in light of increasing ransomware threats and the shift to remote work during the pandemic.